Additional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP
MP3•Episode home
Manage episode 416981893 series 3456244
Content provided by i3 Health and I3 Health. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by i3 Health and I3 Health or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma Live or Virtual Meeting Series: https://www.i3health.com/live/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma%20-%20live%20-%20webinar
…
continue reading
34 episodes